GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (LSE:POLB) » Definitions » Institutional Ownership

Poolbeg Pharma (LSE:POLB) Institutional Ownership : 1.51% (As of May. 02, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Poolbeg Pharma's institutional ownership is 1.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Poolbeg Pharma's Insider Ownership is 9.86%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Poolbeg Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Poolbeg Pharma Institutional Ownership Historical Data

The historical data trend for Poolbeg Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Institutional Ownership Chart

Poolbeg Pharma Historical Data

The historical data trend for Poolbeg Pharma can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30
Institutional Ownership 4.39 2.04 1.51 1.51 1.51 1.51 1.51 1.51 1.51 1.51

Poolbeg Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines